Argenica Therapeutics Ltd Asset Resilience Ratio
Argenica Therapeutics Ltd asset resilience ratio. Argenica Therapeutics Ltd (AGN) has an Asset Resilience Ratio of 0.52% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Argenica Therapeutics Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Argenica Therapeutics Ltd (2022–2022)
Asset resilience ratio of Argenica Therapeutics Ltd from 2022 to 2022. This chart shows how Argenica Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read AGN total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Argenica Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Argenica Therapeutics Ltd balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$50.00K | 0.52% |
| Total Liquid Assets | AU$50.00K | 0.52% |
Asset Resilience Insights
- Limited Liquidity: Argenica Therapeutics Ltd maintains only 0.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Argenica Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Argenica Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Argenica Therapeutics Ltd Asset Resilience Ratio by Year (2022–2022)
Argenica Therapeutics Ltd asset resilience ratio by year from 2022 to 2022. The table below shows the annual Asset Resilience Ratio data for Argenica Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.52% | AU$50.00K ≈ $35.38K |
AU$9.54 Million ≈ $6.75 Million |
-- |
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Aus… Read more